文献速递鼻科

dupilumab治疗CRSwNP停药后临床纵向评估(CLEAR研究)

Clinical Longitudinal Evaluation After Regimen Stop (CLEAR) of Dupilumab in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).
PubMed 文献 · Int Forum Allergy Rhinol · 2026-08-11

本研究为单中心回顾性真实世界研究,纳入46例经dupilumab治疗≥2年且疾病控制良好至优秀的成人CRSwNP患者,停药后随访至12个月。结果显示多数患者在停药后3个月内各项主要指标显著恶化,中位首次症状加重时间为7.6周,87.0%的患者在12个月内重新启用dupilumab,提示完全停药仅对少数患者可行。

要点

  • 长期控制后完全停用dupilumab,多数患者早期复发。
  • 停药后3个月内SNOT-22、VAS、NPS均显著恶化(p<0.001)。
  • 87.0%患者12个月内重新启用dupilumab,主要因鼻部症状复发。

核心结论

  • 长期疾病控制后完全停用dupilumab仅对少数患者可行,多数出现早期复发。
  • dupilumab为疾病控制性而非疾病修饰或治愈性治疗,支持个体化减量而非完全停药。

研究设计与样本

  • 单中心、回顾性、真实世界研究,纳入46例成人CRSwNP患者。
  • 患者接受dupilumab治疗≥2年且疾病控制良好至优秀后停药,随访至12个月。
  • 停药时疾病控制依据EPOS/EUFOREA对齐标准定义(双侧NPS≤2;SNOT-22<20)。

主要发现

  • 中位治疗时长189.7周;停药时平均SNOT-22为10.1±6.1,NPS为0.2±0.5。
  • 停药后3个月内SNOT-22升至36.4±20.0,VAS为5.0±2.7,NPS为1.5±1.9,均p<0.001。
  • 中位首次症状加重时间为7.6周。
  • 87.0%的患者在12个月内重新启用dupilumab,主要因鼻部症状复发。
  • 重新治疗带来快速且显著的临床改善;6例未重启治疗者呈现进行性客观和/或主观恶化。

关键数值与推荐

  • 停药时疾病控制标准:双侧NPS≤2且SNOT-22<20(EPOS/EUFOREA对齐标准)。
  • 纳入标准:成人CRSwNP,dupilumab治疗≥2年,持续良好至优秀疾病控制后停药。

临床怎么用

  • 对长期控制良好的重度Type 2驱动CRSwNP患者,优先考虑个体化剂量递减而非完全停用dupilumab。
  • 停药后应密切监测,尤其在前3个月内,因中位症状加重时间约7.6周。

局限性

  • 单中心、回顾性、真实世界设计。
  • 样本量较小(46例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term management strategies for severe chronic rhinosinusitis with nasal polyps (CRSwNP) increasingly include biologic therapy targeting Type 2 inflammation. However, data on outcomes after complete discontinuation of dupilumab following sustained disease control are scarce. METHODS: In this single-center, retrospective real-world study, adult CRSwNP patients who discontinued dupilumab after ≥ 2 years of treatment and sustained good-to-excellent disease control were included. Disease control at cessation was defined according to EPOS/EUFOREA-aligned criteria (bilateral nasal polyp score [NPS] ≤ 2; SNOT-22 < 20). Patients were followed for up to 12 months. Outcomes included SNOT-22, visual analog scale (VAS), NPS, olfactory function (SSIT-12), relapse timing, and reinitiation of therapy. RESULTS: A total of 46 patients were included (median treatment duration 189.7 weeks). At discontinuation, disease control was excellent (mean SNOT-22 10.1 ± 6.1; NPS 0.2 ± 0.5). Within 3 months, a marked and statistically significant deterioration occurred across all major outcomes (SNOT-22 36.4 ± 20.0; VAS 5.0 ± 2.7; NPS 1.5 ± 1.9; all p < 0.001). Median time to first symptom worsening was 7.6 weeks. Most The majority of patients (87.0%) reinitiated dupilumab within 12 months, primarily due to nasal symptom recurrence. Retreatment led to rapid and significant clinical improvement. Six patients remained off therapy, but demonstrated progressive objective and/or subjective worsening over time. CONCLUSIONS: Complete discontinuation of dupilumab after long-term disease control appears feasible in only a minority of patients and is associated with early relapse in most cases. These findings support the concept of dupilumab as a disease-controlling rather than disease-modifying or curative therapy and favor individualized dose tapering over full cessation in severe Type 2-driven CRSwNP.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Huber P, Lasch M, Volgger V, et al. Clinical Longitudinal Evaluation After Regimen Stop (CLEAR) of Dupilumab in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP). Int Forum Allergy Rhinol. 2026. PMID: 42579396. doi:10.1002/alr.70241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。